STING1 and neoplasm: ATR inhibitors in combination with radiotherapy enhanced the antitumor immune responses to PD-L1 blockade therapies by activating the STING-interferon signaling pathway, enhances the immunogenicity of SCLC and thus promotes anti-tumor immunity (Taniguchi et al., 2024).